Meet Proteona at the 25th Annual Congress of EHA, virtual edition
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Dr Jonathan Scolnick will be presenting at the 25th Annual Congress of the European Hematology Association (EHA), taking place from 11 to 21 June 2020. Dr Scolnick will discuss the application of Proteona’s single cell multi-omics analysis in multiple myeloma treatment decision making.
ESCAPE™ RNA-seq and AI-assisted cell annotation tool can automatically identify the tumor cells and the normal cells within multiple myeloma samples. The RNA and protein expression levels of a therapeutic target can subsequently be analysed on single tumor cells. The information helps clinicians to understand escape mechanisms of cancer cells from previous treatment regimes, and to adjust future therapeutic strategies.
The EHA Annual Congress is the most important hematology conference in Europe. Join Proteona to learn about the latest innovations in the field and to meet with leading haematologists from around the world, all at just a click away!
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.